Sarepta Therapeutics
Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
SRPT Key Statistics
Stock Snapshot
Sarepta Therapeutics(SRPT) stock is priced at $18.76, giving the company a market capitalization of 1.97B. It carries a P/E multiple of -6.50.
On 2025-11-15, Sarepta Therapeutics(SRPT) stock traded between a low of $17.00 and a high of $20.15. Shares are currently priced at $18.76, which is +10.4% above the low and -6.9% below the high.
Sarepta Therapeutics(SRPT) shares are trading with a volume of 8.04M, against a daily average of 8.48M.
In the last year, Sarepta Therapeutics(SRPT) shares hit a 52-week high of $138.81 and a 52-week low of $10.42.
In the last year, Sarepta Therapeutics(SRPT) shares hit a 52-week high of $138.81 and a 52-week low of $10.42.
SRPT News
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock jumped on Friday after the FDA issued a new boxed warning for Elevidys. The updated approval follows recent repor...
Sarepta (SRPT) Therapeutics announced an update to the prescribing information for Elevidys, which it identifies as “the only approved gene therapy for Duchenne...
The U.S. Food and Drug Administration announced it is taking action to approve new labeling submitted by the company that includes the addition of a Boxed Warni...
Analyst ratings
54%
of 26 ratingsMore SRPT News
Sarepta Therapeutics (SRPT) shares drew attention after the company announced mixed outcomes from its pivotal ESSENCE Phase 3 trial. Although the main goal did...
In the past week, Sarepta Therapeutics reported third-quarter 2025 earnings with revenue of US$399.36 million and a net loss of US$179.95 million, alongside ann...